Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells. Saraste M, Penttilä T-L, Airas L Neurol Neuroimmunol Neuroinflamm. 2016 Dec; 3(6):e292. PMID: 27800533. Abstract CommentRecommendBookmarkWatch
